Physician profile
Eugene Khait
NPI 1437333481
$27,556.34
in general payments reported to CMS, 2019-2025
23 companies · $7,164 in 2025
The $7,164 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $5,025 · 2021: $5,672 · 2022: $4,253 · 2023: $2,525 · 2024: $1,706 · 2025: $7,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Food and Beverage: $5,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Food and Beverage | $5,395.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14,762.20 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $7,521.14 | 2024-2025 | Assure Wcd |
| Amgen INC. | $952.91 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $768.95 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $533.29 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $510.99 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $478.94 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $303.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.28 | 2019-2024 | Jardiance |
| Heartflow, INC. | $243.36 | 2024-2025 | |
| Medtronic, INC. | $217.41 | 2021-2025 | Micra, Hawkone, Azure Xt Dr Mri Surescan |
| Irhythm Technologies, INC. | $212.64 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $183.40 | 2022-2025 | Verquvo |
| Pfizer INC. | $181.21 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $162.51 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $50.17 | 2022 | |
| Edwards Lifesciences Corporation | $36.73 | 2025 | Sapien 3 Ultra Resilia |
| Bardy Diagnostics, INC. | $35.92 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.17 | 2021 | |
| Abbott Laboratories | $24.12 | 2024 | Xience Skypoint |
| Vivaquant INC, Dba Rhythm Express | $21.44 | 2025 | Rhythm Express |
| Lexicon Pharmaceuticals, INC. | $20.20 | 2023 | Inpefa |
| Astellas Pharma US INC | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Khait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.